Cardiac and proinflammatory markers predict prognosis in cirrhosis

Liver International

Volumn 34, Issue 6, 2014, Pages

  Wiese, Signe ^a,b   Mortensen, Christian ^b,c   Gøtze, Jens P ^d   Christensen, Erik ^e   Andersen, Ove ^b   Bendtsen, Flemming ^b,c   Møller, Søren ^a,c  

^a Department of Clinical Physiology and Nuclear Medicine Center of Functional and Diagnostic Imaging and Research   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d University of Copenhagen   (Denmark)

^e BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Chronic liver disease; Cirrhotic cardiomyopathy; Inflammation; Portal hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; BINDING PROTEIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; COPEPTIN; CREATININE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH SENSITIVE C REACTIVE PROTEIN; HIGH SENSITIVITY TROPONIN T; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCAHRIDE BINDING PROTEIN; SERUM ALBUMIN I 125; SODIUM; SOLUBLE UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR; TROPONIN T; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; AUTACOID; PLAUR PROTEIN, HUMAN;

ADULT; ALCOHOL ABUSE; ARTERY THROMBOSIS; ARTICLE; ASCITES; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DISEASE; HEART FUNCTION; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PORTAL HYPERTENSION; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; SYSTEMIC VASCULAR RESISTANCE; VENOUS PRESSURE; BLOOD; HEART MUSCLE; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPLANCHNIC BLOOD FLOW;

BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPLANCHNIC CIRCULATION; TROPONIN T;

EID: 84902537355     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12428     Document Type: Article

References (35)

1. Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-78.
2. Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008; 134: 1715-28.
3. Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005; 39(4 Suppl 2): S125-30.
4. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-56, 1256.
5. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353: 139-42.
6. Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-82.
7. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: 105-10.
8. Henriksen JH, Gotze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511-7.
9. Saner FH, Neumann T, Canbay A, et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 2011; 24: 425-32.
10. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
11. Albillos A, de-la-Hera A, varez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363: 1608-10.
12. Mortensen C, Andersen O, Krag A, Bendtsen F, Moller S. High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. Eur J Gastroenterol Hepatol 2012; 24: 619-26.
13. Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 2012; 32: 500-9.
14. Sorensen HT, Thulstrup AM, Mellemkjar L, et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol 2003; 56: 88-93.
15. Moller S, Henriksen JH, Bendtsen F. Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 2003; 284: G970-9.
16. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. Am J Physiol Gastrointest Liver Physiol 2001; 280: G584-94.
17. Alehagen U, Dahlstrom U, Rehfeld JF, Goetze JP. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. Clin Chem 2010; 56: 1718-24.
18. Goetze JP, Dahlstrom U, Rehfeld JF, Alehagen U. Impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement. Clin Chem 2008; 54: 1780-7.
19. Alehagen U, Dahlstrom U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 2011; 305: 2088-95.
20. Hunter I, Alehagen U, Dahlstrom U, et al. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. Clin Chem 2011; 57: 1327-30.
21. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
22. Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010; 12: 338-47.
23. Miller WL, Hartman KA, Grill DE, et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 2012; 98: 389-94.
24. Moller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol 2013; 167: 1101-08.
25. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113: 1958-65.
26. Pateron D, Beyne P, Laperche T, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640-3.
27. Melki D, Lind S, Agewall S, Jernberg T. Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation. Clin Chim Acta 2012; 413: 933-7.
28. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-12.
29. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-47.
30. Logeart D, Beyne P, Cusson C, et al. Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. Am Heart J 2001; 141: 247-53.
31. Jones DE, Hollingsworth K, Fattakhova G, et al. Impaired cardiovascular function in primary biliary cirrhosis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G764-73.
32. Kazankov K, Holland-Fischer P, Andersen NH, et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011; 31: 534-40.
33. Diris JH, Hackeng CM, Kooman JP, et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation 2004; 109: 23-5.
34. Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296-308.
35. Martin-Llahi M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-96.